Results 131 to 140 of about 5,617 (179)

Hematopoietic stem cell gene editing rescues B-cell development in X-linked agammaglobulinemia. [PDF]

open access: yesJ Allergy Clin Immunol
Bahal S   +18 more
europepmc   +1 more source

Cell-penetrating peptide-conjugated, splice-switching oligonucleotides mitigate the phenotype in <i>BTK</i>/<i>Tec</i> double deficient X-linked agammaglobulinemia model. [PDF]

open access: yesRSC Chem Biol
Bestas B   +21 more
europepmc   +1 more source

Severe Tick-Borne Encephalitis (TBE) in a Patient with X-Linked Agammaglobulinemia; Treatment with TBE Virus IgG Positive Plasma, Clinical Outcome and T Cell Responses. [PDF]

open access: yesJ Clin Immunol
Hedin W   +9 more
europepmc   +1 more source

Multiple Colorectal Neoplasms in X-Linked Agammaglobulinemia [PDF]

open access: yesClinical Gastroenterology and Hepatology, 2008
X-linked agammaglobulinemia (XLA) is a primary immunodeficiency disorder caused by germline mutation of the Bruton tyrosine kinase (BTK) gene. It is characterized by disturbed B-cell development, decreased immunoglobulin levels, and increased patient susceptibility to infection.
Brosens, Lodewijk A. A.   +7 more
openaire   +4 more sources

Expression of the Gene Defect in X-Linked Agammaglobulinemia

New England Journal of Medicine, 1986
Although X-linked agammaglobulinemia was one of the first immunodeficiencies described,1 the genetic defect responsible for this disorder has not yet been identified.
Jack Singer, W H Raskind, M E Conley
exaly   +3 more sources

Home - About - Disclaimer - Privacy